Submitted by Anonymous (not verified) on 11 February 2026 - 13:10
Human medicines European public assessment report (EPAR): Imjudo, tremelimumab, Date of authorisation: 20/02/2023, Revision: 9, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Imjudo, tremelimumab, Date of authorisation: 20/02/2023, Revision: 9, Status: Authorised